Gunnel Hallden received the B.S. degree in biochemistry, organic chemistry, and medical physiology from the University of Stockholm and the Karolinska Institute, Sweden in 1985. After graduation, she pursued research projects on peptide hormones at the Karolinska Institute and in the USA at the Stanford University and the University of California at San Francisco (UCSF). She received her Ph.D. degree in endocrinology from the University of California at Berkeley (UCB) in 1995 for work on gastrointestinal cell biology and signalling. From 1995 to 1999, Hallden was a Postdoctoral Scientist at the Departments of Nutrition and Toxicology, and Cell and Molecular Biology at UCB investigating peptide hormone receptor interactions and natural anticancer agents. In 2000-2001, she was a Scientist at the Onyx Pharmaceuticals (Calif, USA) developing oncolytic adenoviral mutants. From 2001 to 2004, Hallden was appointed Senior Postdoctoral Scientist/Group Leader for the Viral and Gene Therapy Program at the Cancer Research UK, Imperial College School of Medicine, London, UK. Presently, she is a Senior Lecturer and Team Leader in Cancer Gene Therapy, at the Barts Cancer Institute, Queen Mary’s School of Medicine and Dentistry (QMUL), London. Her research interests are to find novel targets and treatment strategies for late-stage, treatment-resistant cancers, mainly pancreatic and metastatic androgen-independent prostate cancer. Her research has resulted in the development of several replication-selective adenoviruses that synergistically and selectively enhance antitumour efficacy in combination with cytotoxic drugs and natural anticancer compounds.
Biography Updated on 7 September 2011